HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Record Number Of Mergers Forces US Regulatory Agencies’ Hand On Updating Enforcement Guides

Executive Summary

Chairwoman Lina Khan says concerns about impact on consumer product markets from mergers prompted FTC, working with DoJ, to seek public input on modernizing federal merger guidelines to better detect and prevent illegal, anticompetitive deals in current markets.

You may also be interested in...



‘Revolutionaries’ At FTC Could Give Businesses ‘Very Rough Ride,’ Former Agency Chairman Says

Recently appointed Chairwoman Lina Khan and other "revolutionaries have firmly taken over,” says former FTC chairman Timothy Muris. FTC’s lobbying to restore authority, which SCOTUS struck down, to impose monetary relief orders against marketers linked to false advertising is an example of agency’s direction.

Another Advertising Review For Goli Nutrition: Church & Dwight Challenges Ashwagandha Claims

NAD review of Goli claims, looking at weight loss, physical performance, sexual function and sales claims, recommended it modify advertising to avoid conveying implied product efficacy claims for Ashwagandha Gummies and modify or discontinue qualified physical performance claim about ingredient KSM-66.

Perrigo Has First US Approval For OTC Omeprazole Mini-Capsule

Capsule is 70% smaller than tablets of omeprazole currently available in Prilosec OTC and generic equivalents, including formulations Perrigo provides for its private label and store brand customers.

Topics

UsernamePublicRestriction

Register

RS152120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel